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Abstract
Background: As Lens epithelium-derived growth factor (LEDGF/p75) is an important co-factor involved in HIV-1 integration,
the LEDGF/p75-IN interaction is a promising target for the new class of allosteric HIV integrase inhibitors (LEDGINs). Few
data are available on the genetic variability of LEDGF/p75 and the influence on HIV disease in vivo. This study evaluated the
relation between LEDGF/p75 genetic variation, mRNA expression and HIV-1 disease progression in order to guide future
clinical use of LEDGINs.
Methods: Samples were derived from a therapy-naı¨ve cohort at Ghent University Hospital and a Spanish long-term-non-
progressor cohort. High-resolution melting curve analysis and Sanger sequencing were used to identify all single nucleotide
polymorphisms (SNPs) in the coding region, flanking intronic regions and full 39UTR of LEDGF/p75. In addition, two intronic
tagSNPs were screened based on previous indication of influencing HIV disease. LEDGF/p75 mRNA was quantified in patient
peripheral blood mononuclear cells (PBMC) using RT-qPCR.
Results: 325 samples were investigated from patients of Caucasian (n = 291) and African (n = 34) origin, including Elite
(n = 49) and Viremic controllers (n = 62). 21 SNPs were identified, comprising five in the coding region and 16 in the non-
coding regions and 39UTR. The variants in the coding region were infrequent and had no major impact on protein structure
according to SIFT and PolyPhen score. One intronic SNP (rs2737828) was significantly under-represented in Caucasian
patients (P,0.0001) compared to healthy controls (HapMap). Two SNPs showed a non-significant trend towards association
with slower disease progression but not with LEDGF/p75 expression. The observed variation in LEDGF/p75 expression was
not correlated with disease progression.
Conclusions: LEDGF/p75 is a highly conserved protein. Two non-coding polymorphisms were identified indicating a
correlation with disease outcome, but further research is needed to clarify phenotypic impact. The conserved coding region
and the observed variation in LEDGF/p75 expression are important characteristics for clinical use of LEDGINs.
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Background
Acquired Immunodeficiency Syndrome (AIDS) caused by the
human immunodeficiency virus (HIV) is one of the major
infectious diseases with 34 million people affected world-wide
[1]. The introduction of combination antiretroviral treatment
converted HIV/AIDS from a deadly disease into a chronic
infection [2]. However, short- and long-term side-effects often
challenge life-long antiviral treatment, prompting the need for new
therapeutic strategies. This search has mainly been focussed on
targeting viral enzymes as reverse transcriptase, protease and more
recently integrase [3]. Different steps of the HIV-1 cycle are tightly
dependent on cellular factors and accordingly host factors have
become potential targets for HIV drug development. As an
example, a first drug targeting the CCR5 co-receptor was
approved for treatment of HIV-1 infection [4]. Further unravel-
ling the host – virus interaction not only leads to better
understanding of viral dynamics and disease progression, but also
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paves the way to validate new targets in the treatment of HIV-1
[5]. An increasing number of co-factors is being studied in the
course of new strategies against HIV-1 infection [6].
An important and limiting step during cell infection is the
integration of proviral DNA into host cell DNA, catalyzed by the
viral enzyme integrase (IN). This requires the interaction with
Lens epithelium-derived growth factor p75 (LEDGF/p75). By
interacting with the catalytic core domain of IN, LEDGF/p75
functions as a chromatin tethering factor for the pre-integration
complex, and targets HIV-1 integration towards actively
transcribed genomic regions [7,8,9,10,11,12,13,14]. LEDGF/
p75 is a member of the hepatoma-derived growth factor (HDGF)
related protein family (HRP-family) known as transcriptional co-
activators for heat-shock and stress-related genes
[15,16,17,18,19,20]. It plays a role as anti-apoptotic protein in
diverse oncologic settings [21,22]. The essential role in HIV-1
replication has been elucidated by mutagenesis, RNA interfer-
ence, transdominant expression of protein domains and knock-
out experiments [23,24,25,26,27]. Recently, allosteric inhibitors
of the LEDGF/p75 - IN interaction (LEDGIN) were developed
as a new class of antiretroviral treatment [28]. In vitro data show
that LEDGINs also block the interaction between IN and HRP2,
a second host protein of the HRP-family that contains a
structurally similar integrase binding domain (IBD) and can
substitute for HIV integration in cell lines with LEDGF/p75
knock-down [29].
Several Genome-wide association studies explored the
influence of human genetic variation on HIV-1 replication
and disease progression [30,31,32,33,34]. Genetic variants in
genes associated with HLA-B*57:01 and the HLA-C gene
region, together with the CCR5D32 variant can explain up to
13% of the observed variability in HIV-1 viremia [32] raising
the need for further genetic studies to improve individualized
prognosis in HIV-infected patients. Gene polymorphisms can
be particularly important to predict response to treatment when
drug targets are cellular host proteins [35]. Two studies
investigated genetic variation in the LEDGF/p75 gene (known
as PC4 and SFRS-1 interacting protein-1 or PSIP1). One study
detected rare single nucleotide polymorphisms (SNPs) in the
adjacent domains of LEDGF/p75 integrase binding domains
(IBD) of Caucasian long-term non-progressor patients [36]. The
other study genotyped five pre-defined tagSNPs in two South-
African cohorts. They showed that the minor allele of one
tagSNP was associated with higher CD4 T-cell count, lower
viremia and reduced LEDGF/p75 mRNA expression during
early infection and slower CD4 decline during the chronic
phase. Another tagSNP minor allele was more prevalent in
sero-positives and trended towards association with high
likelihood of HIV-1 acquisition [37]. This data indicate there
can be a correlation between genetic variants in the LEDGF/
p75 domain and HIV disease outcome. However, a compre-
hensive analysis of all genetic variation in the coding region of
LEDGF/p75 has not been performed so far and may provide
information of additional variants with an influence on HIV
disease progression.
The current study aimed at a comprehensive in vivo character-
ization of LEDGF/p75 on both genetic and mRNA level in a large
and ethnically mixed HIV-1 infected patient cohort. We focused
on the association of genetic variation in the full coding
region+39UTR of the LEDGF/p75 gene and HIV-1 disease
progression and on the link of genetic variants with LEDGF/p75
and HRP2 mRNA expression levels.
Methods
Patient population
The study included chronically HIV-1 infected patients from
the Aids Reference Center at Ghent University Hospital (n = 187)
and HIV-1 long-term non-progressors (LTNP; n = 138) from the
LTNP cohort of the Spanish AIDS Research Network (See
Table 1). Samples from the LTNP cohort were kindly provided by
the HIV BioBank integrated in the Spanish AIDS Research
Network (RIS) [38]. Samples were processed and frozen imme-
diately after collection. The Ghent patients had a therapy-naive
follow-up period of at least two years with regular CD4 count and
plasma HIV RNA determination (three times/year). They
comprised patients from Caucasian (81.2%) as well as African
(18.2%) descent. Data on HIV-1 subtype were available for 83%
of patients with 70% of them harboring an HIV-1 B-subtype. The
LTNP cohort were all of Caucasian origin, had a documented
HIV-1 infection .10 years, consistent CD4 count above 500
cells/ml and viral load below 10,000 copies/ml in the absence of
therapy. The slope of CD4 decline and the average plasma HIV
viral load were determined for all patients based on at least four
CD4+ T-cell counts and plasma HIV RNA measurements on
samples collected with minimum three months’ time interval
during the therapy-naive follow-up period. Classification of
patients according to disease progression was based on broadly
applied clinical definitions [39,40,41,42,43]: LTNP elite control-
lers (LTNP-EC) are long-term non-progressors (10 year follow-up,
CD4 .500cells/mL) maintaining an undetectable viral load
without antiretroviral therapy (n = 48), LTNP viremic controllers
(LTNP-VC) are long-term non-progressors harboring less than
2000 HIV RNA copies/ml without therapy in 75% of the
measurements (n = 63), viremic non-controllers (LTNP-NC) are
long-term non-progressors with a viral load between 2000 and
10,000 copies/ml (n = 66). Rapid progressors (RP) are non-LTNP
patients with CD4 decline of more than 100 cells/ml per year
(n = 35) and normal progressors (NP) are non-LTNP with a CD4
decline less than 100 cells/ml per year (n = 113). Ethical approval
was obtained from Ethics Committee of Ghent University
Hospital (Reg nr B67020071646) and Instituto de Salud Carlos
III (Ref CEI PI 33_2010-v3). All participants provided written
informed consent.
PSIP1 genotyping
After gDNA extraction from whole blood (Blood mini kit,
Qiagen), 23 fragments were amplified by PCR, spanning the
complete coding region of PSIP1, 39UTR and on average 25
basepairs of the flanking intronic regions (see Figure 1). Two
intronic tagSNPs described by Madlala et al. were analyzed as well
[37]. Primers were designed with Lightscanner software (Idaho
Technologies) and listed in Table S1. Single nucleotide polymor-
phisms were screened by high resolution melting curve (HRM)
analysis (Lightscanner, Idaho Technologies) with high sensitivity
detection and auto-grouping [44,45]. Bi-directional Sanger
sequencing with Big Dye Terminator (ABI 3730 xl Sequencer,
Applied Biosystems) was performed on all samples with aberrant
melting curves for identification of SNPs. This methodology was
validated by direct comparison of HRM data with Sanger
sequencing in a large group of samples (n = 50). When necessary,
detection sensitivity levels were adjusted to assure 100% sensitivity
for all variants. All SNPs in the coding region and infrequent SNPs
in the non-coding region were re-tested using separate DNA
samples to independently verify the results. The impact of SNPs on
protein structure was assessed with SIFT (Sorting Intolerant from
Tolerant) and Polyphen score (Polymorphism Phenotyping) for
LEDGF/p75 Variants in Relation with HIV-1 Disease
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variants in the coding region and MaxEnt scan and NNSPlice for
intronic variants [46,47,48,49]. In silico evaluation of the amino
acid code of PSIP1 gene product from different primates
(Chimpanzee, Gorilla, Gibbon, Bushbaby) was performed based
on the consensus sequences found in Ensembl database [50].
mRNA gene expression analysis
RNA was isolated using Trizol LS reagent (Invitrogen,
Carlsbad, USA) from freshly extracted 56106 peripheral blood
mononuclear cells (PBMCs) of patients from the Ghent cohort
containing genetic variants that indicated clustering in disease
progression groups. Patients not harboring PSIP1 genetic variants
were used as controls. A strict protocol in accordance with MIQE
guidelines was followed [51]. After Dnase treatment (Dnase I,
Ambion), the RNA integrity was assessed using automated
electrophoresis (Experion, Bio-Rad). Reverse transcription was
performed on 400 ng RNA with the iScript complementary DNA
(cDNA) synthesis kit and random hexamere primers (Bio-Rad).
LEDGF/p75 specific mRNA (i.e. not including LEDGF/p52) and
HRP2 mRNA expression was quantified by qPCR using dual-
labelled hydrolysis probes and LightCyclerH 480 Probes Master-
mix on a LC480 platform (Roche Diagnostics). After qPCR, the
most stable and optimal number of reference genes were validated
from a panel of eight reference genes with GeNorm, NormFinder
and BestKeeper software [52] (see also Figure S1). The geometric
mean of the two most stable reference genes (B2M and YMHAZ)
was used as normalization factor for the calculation of relative
mRNA expression quantities (qBase Plus, Biogazelle, Ghent,
Belgium [53]).
Statistical analysis
Linkage disequilibrium between different variants was assessed
with principal component analysis. Observed minor allele
frequencies of individual SNPs were compared to expected
frequencies per ethnicity with Fisher exact test (SPSS 19 software).
The same analysis was performed to distinguish clustering of
alleles in disease progression subgroups. Bonferroni correction for
multiple sampling was applied. After normality testing with
Shapiro-Wilk, Analysis of variance (ANOVA) was used to
determine differences in gene expression between different disease
progression groups. Of the genetic variants in the coding region
and in the non-coding region with significant clustering in one or
more disease progression groups, the influence on gene expression
(LEDGF/p75 and HRP2 mRNA) and disease progression (CD4
slope and average viral load) was analyzed for significance by
Mann-Whitney U and Kruskal-Wallis test (SPSS 19 software).
Pearson correlation and paired T-tests were used to assess
correlation between gene expression data and the parameters of
disease outcome.
Results
The study comprised 325 chronically infected HIV-1 patients
from a diverse ethnic background with an average follow-up time
of 15 years (Table 1). Patients were grouped into five distinct
disease progression categories as outlined in Methods. Thirty-four
percent of study subjects were either LTNP viremic or elite
controllers. CD4 decline or average plasma viral load was
independent from HIV subtype. The sensitivity of HRM curve
analysis for SNP detection was 100% for all amplicons, the
specificity ranged from 82% to 97%. In total 23 individual SNPs
were detected, five in coding regions of the gene, six in intronic
regions flanking the coding sequences and 12 in the 39UTR
(Table 2 and 3). Most SNPs were previously annotated, two are
newly described in this work and submitted for further reference at
dbSNP database (NCBI). Of all SNPs, minor allele frequencies
(MAF) were calculated and genotype frequencies were determined
to be in accordance with Hardy-Weinberg equilibrium. As there
can be large differences in MAF between Africans and Europeans,
analyses for both ethnicities were separately performed. Two SNPs
(rs35678110 and rs13248) were excluded from further analysis, as
Table 1. Patient characteristics.
Ghent cohort
(N=187)
RIS Cohort
(N=138) Overall (N=325)
African
(N=34)
Caucasian
(N=291)
Age at diagnosis, median
years (IQR)
34 (28–40) 25 (22–30) 29 (24–37) 33 (26–39) 31 (24–36)
Follow-up time, median
years (IQR)
8 (6–11) 22 (20–25) 15 (7–22) 8 (6–11) 15 (8–23)
Sex, N (%) Female 45 (24,1) 48 (34,5) 93 (28,4) 23 (67,7) 70 (24,1)
Male 142 (75,9) 90 (65,5) 232 (71,6) 11 (32,3) 221 (75,9)
Ethnicity, N (%) African 34 (18,2) 0 (0) 34 (10,5)
Caucasian 153 (81,2) 138 (100) 291 (89,5)
Disease progression
(N, %)
LTNP - Elite controller 6 (3,2) 42 (30,4) 48 (14,8) 2 (5,9) 46 (15,8)
LTNP - Viremic controller 16 (8,6) 47 (34,1) 63 (19,4) 7 (20,6) 56 (19,2)
LTNP - Non controller 17 (9,1) 49 (35,5) 66 (20,3) 4 (11,8) 62 (21,3)
Normal progressor 113 (60,4) 0 (0,0) 113 (34,8) 19 (55,9) 94 (32,3)
Rapid progressor 35 (18,7) 0 (0,0) 35 (10,8) 2 (5,9) 33 (11,3)
Current ART, N (%) Yes 87 (46,4) 18 (12,9) 105 (32,3) 13 (38,2) 92 (31,6)
No 100 (53,6) 120 (87,1) 220 (67,7) 21 (61,8) 199 (68,4)
Overview of the patient characteristics, divided for Ghent and RIS cohort and per ethnicity (Africans, Caucasians). The number of patients per subcategory is presented
for sex, ethnicity, disease progression groups and current antiretroviral treatment.
IQR = interquartile range; N =number; LTNP= long-term non-progressor; ART = antiretroviral treatment.
doi:10.1371/journal.pone.0050204.t001
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they did not meet the Hardy-Weinberg law. The observed MAFs
of individual SNPs were compared with expected MAFs on
population level per ethnicity. In order to detect clustering in
disease progression groups, the MAFs in subgroups were
calculated and compared. We did not detect linkage disequilib-
rium between different SNPs with higher MAF.
Genetic variants of PSIP1 in the coding region
In the full coding sequence of PSIP1, five SNPs were detected, of
which two were not altering the encoded amino-acid (silent
mutations) and three were non-synonymous SNPs (Table 2). All
these variants have been annotated before and had low abundance
[54]. Observed minor allele frequencies were compared to
expected frequencies per ethnicity, in comparison with data from
HapMap and dbSNP database [55,56]. Fisher exact tests were
performed to detect significant lower or higher MAF compared to
a randomly selected patient population (Table 2). When compar-
ing the MAFs between the different disease progression groups, no
clustering of these variants in one or more subcategories could be
detected (data not shown). Kruskal-Wallis test (wild-type versus
minor-allele) failed to reveal an association between genetic
variants in the coding region and CD4 slope or average viral
load. LEDGF/p75 mRNA expression levels did not differ for
those patients harboring these SNPs (Figure 2).
Of the two synonymous variants, rs2821529 (S116S) was more
abundant and showed comparable MAF to the expected
frequencies, both in Africans and Caucasians. No link with disease
progression (CD4 decline, average viral load) or LEDGF/p75
Figure 1. LEDGF/p75 protein domains, gene structure and primate alignment. LEDGF/p75 functional protein domains (green) with the
integrase binding domain (IBD, indicated in red) and the PWWP domain, which regulates chromatin association. LEDGF/p75 spliced RNA with
different exons (light and dark purple) is linked to the protein domains. The third line represents the PSIP1 gene region with the coding regions
(purple) and non coding regions (introns are grey, 59UTR and 39UTR are respectively orange and yellow). The location of the discussed SNPs in this
work is indicated (red arrows: SNPs detected after screening; blue arrows: 2 tagSNPs in African cohort). The second panel shows the LEDGF/p75
protein alignment of humans and four primate species based on the reference sequences. The integrase binding domain (red box) is indicated,
showing no variation in the four primates. PWWP=proline-tryptophan-tryptophan-proline domain; NLS =nuclear localization signal; AT = adenine-
thymine rich DNA binding region; IBD= integrase binding domain; UTR= untranslated region.
doi:10.1371/journal.pone.0050204.g001
Table 2. Observed genetic variants in the PSIP1 coding region.
dbSNP rs number HGVS name
SNP
location African Caucasian
Amino acid
change
SIFT
score POLYPHEN score
NM_033222.3 MAF exp MAF obs MAF exp MAF obs
rs2821529 c.348T.C Exon2 0,169 0,107 0,042 0,039 S116S - -
rs139433616 c.402T.C Exon5 NA 0,000 NA 0,002 T134T - -
rs188943134 c.743C.T Exon8 NA 0,000 NA 0,002 P248L 0,18 0,045
rs61744944 c.1415A.T Exon13 0,034 0,059 NA 0,002 Q472L 0,01 0,007
rs35678110 c.1432C.G Exon14 0,025 0,000 NA 0,004{ L478V 0,21 0,049
{signifies variants not in accordance with Hardy Weinberg law.
Overview of the observed SNPs in the PSIP1 coding region for LEDGF/p75. Both expected and observed minor allele frequencies (MAF) are shown per ethnicity. The SIFT
score ranges from 0 to 1. The amino acid substitution is predicted as damaging if the score is ,=0.05, and tolerated if the score is .0.05. The POLYPHEN score ranges
from 0.00 to $2.00. The amino acid substitution is predicted possibly damaging if the score is $1.50 and probably damaging if the score is $2.00.
HGVS=Human Genomic Variation Society; SNP = single nucleotide polymorphism; MAF=minor allele frequency; NA= not assessed; rs = referenced SNP id number; –
means no impact due to silent mutation.
doi:10.1371/journal.pone.0050204.t002
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mRNA expression could be established (Figure 2). Only one
Caucasian patient harbored SNP rs139433616 (T134T), from
whom no mRNA for further analysis could be obtained.
The non-synonymous SNPs rs61744944 coding for Q472L
missense variant and rs188943134 coding for P248L were both
infrequent in Caucasian. SIFT and PolyPhen in silico analysis of
these variants did not indicate a major impact on protein structure
and function [54] (Table 2). The Q472L variant was observed
mainly, but not exclusively in Africans and is located outside the
known important functional domains. The P248L variant was
detected in one Caucasian normal progressor with an average viral
load of 5.17 log10 copies/ml. The mutation is also located outside
the known important domains.
The non-synonymous SNP (rs35678110), coding for the L478V
was present in one Caucasian viremic controller as homozygous
allele variant. This amino-acid is situated in a helix-turn-helix
motif outside the integrase binding domain. This SNP was
however excluded from further analysis due to Hardy-Weinberg
disequilibrium. SIFT and Polyphen scores indicated good
functional tolerance in silico.
Genetic variants of PSIP1 in intronic regions
In the flanking regions of the coding sequences, four intronic
SNPs were detected, of which one previously unknown heterozy-
gous intronic variant in one patient (ss536106972) (Table 3).
Intronic SNP rs2737828, upstream of exon 4, was significantly
less abundant in HIV-positive Caucasians compared to Hapmap
and dbSNP randomly selected patient population (p,0.0001).
There was no significant clustering in patients with long-term non-
progression, nor an association with CD4 slope (p = 0.688) or
average viral load (p = 0.702) (Figure 3A). A non-significant trend
towards lower LEDGF/p75 mRNA expression levels (p = 0.053)
was detected in these patients compared to the wild-type genotype.
HRP2 expression was not correlated with rs2737828 minor alleles
(p = 0.171) (Figure 3B).
For intronic SNP rs16933270, mainly observed in the African
subgroup and only in one Caucasian, the MAF was comparable
with expected frequencies in Africans, but was relatively more
prevalent in the LTNP patients. This variant was associated with
slower CD4 decline (p = 0.020) but not with viral load levels, nor
with LEDGF/p75 or HRP2 mRNA expression (p = 0.181 and
p = 0.150, respectively) (Figure 3A and 3B). A multivariate analysis
taking the viral load set-point and LEDGF/p75 mRNA expression
into account, confirmed this impact on CD4 slope (p = 0.025). For
intronic SNP rs2795128 the observed MAFs were in accordance
with the expected frequencies both for Africans as for Caucasians.
The minor alleles did not cluster in LTNP groups.
The allele frequencies of two intronic tagSNPs in Africans, i.e.
rs2277191 and rs12339417, were additionally determined [37].
Both tagSNPs were abundant in the African subgroup and MAFs
were in line with expected frequencies. However, no correlation
with CD4 decline or LEDGF/p75 mRNA expression could be
confirmed in the cohort. It is interesting to notice that the minor
allele of rs12339417 is considered the wild-type allele in Africans.
Genetic variants in the 3’untranslated region
The 39 untranslated region (UTR) harbored 12 different genetic
variants, one of which was not described previously (Table 3). For
rs2737835, a non-significant trend towards association of minor
SNP alleles with slower CD4 decline (p = 0.058) was observed in
Table 3. Observed genetic variants in the PSIP1 non-coding region.
dbSNP rs number HGVS name SNP location African Caucasian
NM_033222.3 MAF exp MAF obs MAF exp MAF obs
ss536106972 c.1409-G.C Intron1 NA 0,000 NA 0,008
rs2277191 c.-142+226C.T Intron1 0,034 0,103 NA 0,011
rs2795128 c.73-59G.A Intron2 0,124 0,109 0,044 0,066
rs12339417 c.149+8064G.A Intron3 0,686 0,638 0,119 0,148
rs2737828 c.289-29T.A Intron4 NA 0,000 0,15 0,0281
rs16933270 c.1421-48T.C Intron14 0,146 0,103 0,000 0,002
rs188404574 c.*30T.G 39UTR NA 0,000 NA 0,002
rs144536781 c.*410G.T 39UTR NA 0,016 NA 0,000
rs114211035 c.*464A.G 39UTR 0,085 0,000 NA 0,002
rs78732111 c.*592G.C 39UTR 0,085 0,000 NA 0,002
rs2737835 c.*620G.T 39UTR 0,033 0,129 0,108 0,076
rs41306098 c.*684G.A 39UTR NA 0,032 0,092 0,056
rs2665515 c.*775C.T 39UTR 0,142 0,094 0,067 0,066
rs139069294 c.*790A.G 39UTR NA 0,031 NA 0,000
ss536106976 c.*815G.T 39UTR NA 0,000 NA 0,003
rs74366322 c.*1079T.C 39UTR 0,186 0,200 NA 0,000
rs13248 c.*1232G.A 39UTR 0,611 0,500{ 0,004 0,015{
rs41268959 c.*1268G.A 39UTR NA 0,000 0,025 0,016
{signifies variants not in accordance with Hardy Weinberg law.
1signifies p,0.001, after Bonferroni correction.
Overview of the observed SNPs in the PSIP1 non-coding region. Both expected and observed minor allele frequencies (MAF) are shown per ethnicity.
HGVS =Human Genomic Variation Society; SNP= single nucleotide polymorphism; MAF=minor allele frequency; NA= not assessed; rs = referenced SNP id number;
ss = submitted SNP id number.
doi:10.1371/journal.pone.0050204.t003
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Caucasian but not in African patients (Figure 3A). There was no
correlation with average viral load (p = 0.931). The expression
levels of both LEDGF/p75 (p = 0.093) and HRP2 (p = 0.317)
mRNA were not associated with the presence of these minor
alleles (Figure 3B). The SNP rs2737835 is located in a 39UTR
region with higher variability, although no linkage disequilibrium
with other variants in this region could be determined.
The other 11 variants did not reveal MAFs aberrant from
expected frequencies, eight variants were infrequent both in
Africans and in Caucasians. None of these clustered in LTNP
subgroups.
LEDGF/p75 and HRP2 mRNA expression levels
Gene expression analysis was performed on a subset of patients
from the Ghent cohort (n = 104). Validation of reference genes for
normalization with the GeNorm, NormFinder and BestKeeper
software gave congruent results (Figure S1). The geometric mean
of the two most stable genes (B2M and YMHAZ) was used for
normalization of gene expression data.
We could not demonstrate significant differences in expression
levels between patients who received cART and those who were
therapy-naı¨ve. No statistical significant differences in either
LEDGF/p75 or HRP2 mRNA expression were observed between
the five disease progression groups with ANOVA. There was no
correlation between LEDGF/p75 expression and the major
disease outcome parameters (CD4 decline and average viral load).
We could not establish an inverse correlation between LEDGF/
p75 and HRP2 expression (Pearson r = 0.490; p =,0.001)
(Figure 4A). The biological variability of LEDGF/p75 expression
was determined in 24 patients by analyzing samples obtained from
two different time-points. Pearson test indicated correlation
(r = 0.427; p = 0.033) and the paired T-test could not determine
a significant difference in the means between the groups
(p = 0.937) (Figure 4B). Inter-patient variability ranged from 7.7-
fold expression for LEDGF/p75 till 37-fold for HRP2.
Discussion
Small molecules inhibiting the interaction between host-factor
LEDGF/p75 and the viral enzyme IN form a promising new class
of antiretroviral drugs targeting the integration step of HIV-1
replication cycle [28]. Increasing data indicate that genetic
variation in host genes can influence HIV-1 disease susceptibility,
evolution or therapy response [57]. Since there is little in vivo
knowledge of the LEDGF/p75-IN interplay, the present study
focused on a comprehensive characterization of this host-factor in
a large and diverse patient cohort, on the levels of genetic
background and mRNA expression.
The data indicate that the coding region of LEDGF/p75 is
highly conserved. Of the 35 annotated genetic variants in
HapMap (most of them extremely infrequent in a reference
population), only five were detected in a cohort of 325 HIV-1
positive patients. Three non-synonymous SNPs were low-abun-
dant and there was no in silico indication that they had a major
impact on the phenotype. Functional evaluation needs to be
performed to confirm these predictions. For rs61744944 (Q472L),
experimental data previously showed no alteration of the
LEDGF/p75 - IN binding affinity and the near-complete rescue
of HIV-1 infection by mutant LEDGF/p75 [37]. However, this
does not exclude the possibility of changes in other functions such
as integration site distribution. The low MAFs of these variants in
the present cohort were insufficient to detect a more subtle impact
on disease progression. Patients harboring these variants had
normal levels of LEDGF/p75 mRNA expression. One homozy-
gous missense variant (L478V, rs35678110) was detected in one
LTNP viremic controller. Unfortunately, no further expression
data could be obtained for this patient.
Alignment of consensus sequences of PSIP1 gene products from
different species (Chimpanzee, Gorilla, Gibbons) revealed a highly
conserved protein along evolutionary lines, suggesting the
important biological function of this gene (Figure 1).
Three SNPs were described with indications for a weak
association with HIV disease outcome, situated either in intronic
sequences (rs16933270, rs2737828) or in the 39UTR (rs2737835).
In HIV-infected Caucasian patients, rs2737828 was significantly
underrepresented and showed a non-significant trend towards
lower LEDGF/p75 mRNA expression. This might suggest a
protective role of this variant in acquiring HIV-1 without affecting
disease evolution, but the cross-sectional study design and the lack
Figure 2. Phenotypic impact of observed genetic variants in
the PSIP1 coding region. Box-plots showing the association of
individual observed SNPs in the coding region with CD4 decline (top),
average log viral load (middle) and LEDGF/p75 mRNA expression
(bottom).The data are combined for Africans and Caucasians. SNPs not
in accordance with Hardy-Weinberg law (rs35678110) were excluded. In
case of insufficient data to create a boxplot (limited amount of data
points) a bar representing the mean of the values is shown.
doi:10.1371/journal.pone.0050204.g002
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of a highly-exposed sero-negative or healthy control arm do not
allow to establish susceptibility associations. The underrepresen-
tation of this variant in Caucasian HIV-1 patients needs to be
confirmed in different cohorts, since only limited data is available
on the geographic distribution of this SNP. In African patients,
there was a clustering of rs16933270 minor alleles in patients with
slower CD4 decline but no impact on viral load set-point or
LEDGF/p75 expression levels. Although similar viral load levels
are maintained, some LEDGF/p75 haplotypes could result in a
better CD4+ T-cell survival. Low sample size in the African sub-
cohort however can introduce bias in these results. The
investigation of this variant in a larger cohort of African HIV-1
patients to further assess its impact is recommended. Splice-site
finders could not exclude that rs2737828 and rs16933270 had the
potential to create a branch point sequence and alter splicing,
although no minor splice variants were detected. Variant
rs2737835 showed a non-significant tendency towards slower
CD4 decline but not towards a lower average viral load. Based on
miRNA databases (Patrocles finder), this 39UTR SNP could be the
target for miRNA binding (hsa-mir-1274a), leading to mRNA
destabilization and lower protein levels.
The present data did not confirm the association of African
tagSNP rs12339417 with delayed CD4 decline in a chronic
infection phase. It must be noted that the small sample size of the
African sub-cohort and larger genetic diversity in Africans from
different regions could explain part of these findings. Besides this,
lower LEDGF/p75 expression levels associating with the minor
allele were previously only seen in a sero-converter/early infection
cohort and it might be possible that LEDGF/p75 levels mainly
affect initial HIV infection risk and early replication events.
Alternatively, the use of only one reference gene (GAPDH) as
normalization strategy in the gene expression assays might have
Figure 3. Phenotypic impact of three genetic variants in the PSIP1 non-coding region. (A) Differential CD4 decline for patients carrying
wild-type or variant alleles of rs2737828 and rs2737835 (Caucasian) and rs16933270 (African), based on the mean CD4 slope and a similar starting
point. P values to estimate significance of difference are indicated. (B) Differential expression of LEDGF/p75 mRNA and HRP2 mRNA in PBMCs from
patients carrying wild-type or variant alleles of rs2737828 and rs2737835 (Caucasian) and rs16933270 (African). Horizontal bars indicate the mean
expression levels.
doi:10.1371/journal.pone.0050204.g003
Figure 4. Biological variability and correlation of LEDGF/p75 mRNA with HRP2 mRNA expression. (A) Scatter-plot showing LEDGF/p75
mRNA and HRP2 expression in identical patient samples (n = 68). Pearson r-values and p-values are indicated. (B) Scatter-plot showing the biological
variation of LEDGF/p75 mRNA expression in two samples from 24 patients at different time points. t1 = time point 1; t2 = time point 2.
doi:10.1371/journal.pone.0050204.g004
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introduced additional bias and hampers comparison [52]. In our
assays, normalization with only one reference gene resulted in a
27% increase in variability compared to the standard procedure
with two validated reference genes (data not shown).
Relatively stable inter-individual LEDGF/p75 mRNA expres-
sion levels were detected in vivo. This variance was not related to
genetic polymorphisms in the coding region or 39UTR. Low levels
of LEDGF/p75 expression, linked with decreased integration in
transcriptional active regions in vitro, did not result in lower viral
load [23]. In addition, there was no correlation between low
LEDGF/p75 mRNA expression and CD4 decline. Previous in
vitro studies revealed that LEDGF/p75 knockdown might be
rescued by HRP2, which harbors a similar IN-binding domain
[29]. Consequently, the expression of HRP2 was investigated to
assess whether low levels of LEDGF/p75 are correlated with
higher levels of HRP2 and to see if this rescue mechanism is also
present in vivo, but this was not observed. In vitro studies revealed
that low levels of LEDGF/p75 are sufficient to completely rescue
HIV-1 integration [58]. Other still unknown factors or a more
important effect of LEDGF/p75 during early replication might
provide further explanation for the observed lack of correlation
between LEDGF/p75 expression levels and disease outcome in
chronically infected patients. It must be noted that mRNA was
extracted from PBMCs, containing not only CD4+ but also CD8+
and B-lymphocytes, and therefore representing average expression
levels of these cells. The obtained results did not motivate us to
further analyze the 59 UTR and promoter region of PSIP1.
Because of the limited phenotypic effect of non-coding SNPs (on
for instance tertiary structure) and the observed conservation of
the complete coding region of LEDGF/p75, our data can provide
further validation of the LEDGF/p75 – IN interaction as a
promising target for antiretroviral treatment. The relatively stable
expression of their target shows that LEDGINs could be broadly
applicable and provide a good and durable inhibitory effect.
In general, the results of this study underscore the importance of
detecting rare variants in genes with a high probability of
influencing disease outcome in distinct populations. In contrast
with Genome-wide association studies, which are designed to
reveal genotype-phenotype relations with common variants, rare
variants which show an impact in well-chosen and defined patient
populations can help elucidate functional roles of the gene of
interest.
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